Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,665 followers.

RT @FrontOncology: New research: Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer:…

08 Oct 2023

Reply Repost Favourite

New research: Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression: Breast cancer is the most commonly diagnosed cancer… #oncology h

08 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.